Alkermes’ Antipsychotic Clears US FDA Panel Amid Calls For Broader Professional Education Plan

 
• By Sue Sutter

Communication and education on samidorphan’s opioid antagonistic effects should focus on health care providers that prescribe opioids as well as psychiatrists that prescribe olanzapine, advisory committee says in endorsing the safety and efficacy of ALKS 3831.

FDA Advisory Committee Feature image
Alkermes proposes to market the drug to treat schizophrenia and bipolar disorder in adults. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers